lncRNA TUG1 Facilitates Colorectal Cancer Stem Cell Characteristics and Chemoresistance by Enhancing GATA6 Protein Stability

Figure 2

Effect of lncRNA TUG1 on oxaliplatin resistance of CRC stem cells. (a) lncRNA TUG1 was silenced in the CD133⁺/CD44⁺ cells isolated from HCT-116 and SW480 cells, and then, the cells were treated with 0, 1, 2, 4, 8, and 16 μM oxaliplatin for 48 h. Cell Counting Kit-8 (CCK-8) assay was performed to assess the viability of CD133⁺/CD44⁺ isolated from HCT-116 and SW480 cells. (b) lncRNA TUG1 was silenced in the CD133⁺/CD44⁺ cells isolated from HCT-116 and SW480 cells, and then, the cells were treated with 4 μM oxaliplatin for 48 h. The apoptosis of CD133⁺/CD44⁺ isolated from HCT-116 and SW480 cells was detected using flow cytometry. (c) The quantitative results of cell apoptosis. (d) lncRNA TUG1 was overexpressed in the CD133⁺/CD44⁺ cells isolated from HCT-116 and SW480 cells, and then, the cells were treated with 0, 1, 2, 4, 8, and 16 μM oxaliplatin for 48 h. Analysis of the viability of CD133⁺/CD44⁺ isolated from HCT-116 and SW480 cells by CCK-8 assay. (e) lncRNA TUG1 was overexpressed in the CD133⁺/CD44⁺ cells isolated from HCT-116 and SW480 cells, and then, the cells were treated with 4 μM oxaliplatin for 48 h. Detection of the apoptosis of CD133⁺/CD44⁺ isolated from HCT-116 and SW480 cells using flow cytometry. (f) The quantitative analysis of cell apoptosis. , , and vs. si-NC or pc-NC.

(a)

(b)

(c)

(d)

(e)

(f)